{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:54:08Z","timestamp":1788976448121,"version":"build-2803163510"},"reference-count":69,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Urolithiasis (UL) is increasingly prevalent due to rising cardiorenometabolic diseases, posing significant management challenges despite advances in urological techniques. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, primarily used for type 2 diabetes mellitus, chronic kidney disease, and heart failure, have emerged as a potential novel approach for UL treatment. These inhibitors may help reduce the risk of urolithiasis, particularly in patients with diabetes, by improving glycemic control and altering urinary chemistry, which are crucial factors in stone formation. However, the changes in urinary composition induced by SGLT2 inhibitors might also increase the risk of uric acid stone formation. This review evaluates the potential of SGLT2 inhibitors in managing UL, highlighting both the benefits and the risks. While these inhibitors show promise in reducing new and recurrent urinary stones in patients with diabetes, data on their effects in patients without diabetes who form stones are limited. Current human evidence largely comes from post hoc analyses of randomized controlled trials (RCTs) and large-scale database studies, with only one study providing detailed stone composition data. Experimental studies in animal models and cell lines have focused on calcium oxalate (CaOx) stones, showing that SGLT2 inhibitors specifically target CaOx stone formation and related renal inflammation. Although primarily studied for CaOx stones, their potential impact on other calcium-containing stones, such as calcium phosphate, remains promising. Further research is needed to explore their therapeutic potential and optimize treatment strategies.<\/jats:p>","DOI":"10.3390\/jcm13196017","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T12:22:48Z","timestamp":1728476568000},"page":"6017","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["SGLT2 Inhibitors and Their Effect on Urolithiasis: Current Evidence and Future Directions"],"prefix":"10.3390","volume":"13","author":[{"given":"\u017divka","family":"Dika","sequence":"first","affiliation":[{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"},{"name":"Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3523-6262","authenticated-orcid":false,"given":"Marijana","family":"\u017divko","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kljaji\u0107","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2546-4632","authenticated-orcid":false,"given":"Bojan","family":"Jelakovi\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Zagreb, \u0160alata 3, 10000 Zagreb, Croatia"},{"name":"Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, Ki\u0161pati\u0107eva 12, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6807203","DOI":"10.1155\/2022\/6807203","article-title":"Epidemiological Trends of Urolithiasis at the Global, Regional, and National Levels: A Population-Based Study","volume":"2022","author":"Qian","year":"2022","journal-title":"Int. J. Clin. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Stamatelou, K., and Goldfarb, D.S. (2023). Epidemiology of Kidney Stones. Healthcare, 11.","DOI":"10.3390\/healthcare11030424"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ajur.2018.08.007","article-title":"Epidemiology of urolithiasis in Asia","volume":"5","author":"Liu","year":"2018","journal-title":"Asian J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00345-017-2008-6","article-title":"Epidemiology of stone disease across the world","volume":"35","author":"Sorokin","year":"2017","journal-title":"World J. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Moftakhar, L., Jafari, F., Ghoddusi Johari, M., Rezaeianzadeh, R., Hosseini, S.V., and Rezaianzadeh, A. (2022). Prevalence and risk factors of kidney stone disease in population aged 40-70 years old in Kharameh cohort study: A cross-sectional population-based study in southern Iran. BMC Urol., 22.","DOI":"10.1186\/s12894-022-01161-x"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4103\/1319-2442.152557","article-title":"Epidemiology of urolithiasis with emphasis on ultrasound detection: A retrospective analysis of 5371 cases in Saudi Arabia","volume":"26","author":"Ahmad","year":"2015","journal-title":"Saudi J Kidney Dis Transpl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/j.ajkd.2012.12.028","article-title":"Association of metabolic syndrome traits and severity of kidney stones: Results from a nationwide survey on urolithiasis in Japan","volume":"61","author":"Kohjimoto","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4103\/1947-2714.145477","article-title":"The Risk of Coronary Heart Disease in Patients with Kidney Stones: A Systematic Review and Meta-analysis","volume":"6","author":"Cheungpasitporn","year":"2014","journal-title":"N. Am. J. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.2013.8780","article-title":"History of kidney stones and the risk of coronary heart disease","volume":"310","author":"Ferraro","year":"2013","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1681\/ASN.2010030253","article-title":"Kidney Stones Associate with Increased Risk for Myocardial Infarction","volume":"21","author":"Rule","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.juro.2015.12.069","article-title":"Nephrolithiasis and Risk of Incident Bone Fracture","volume":"195","author":"Taylor","year":"2016","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.2215\/CJN.05811108","article-title":"Kidney stones and the risk for chronic kidney disease","volume":"4","author":"Rule","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2215\/CJN.03210312","article-title":"Urolithiasis and the Risk of ESRD","volume":"7","author":"Lieske","year":"2012","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_14","first-page":"e86","article-title":"Kidney stones: A global picture of prevalence, incidence, and associated risk factors","volume":"12","author":"Romero","year":"2010","journal-title":"Rev. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11255-023-03784-x","article-title":"The association of dyslipidemia with kidney stone: Result from the NHANES 2007\u20132020","volume":"56","author":"Gao","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2215\/CJN.04960513","article-title":"Kidney stones and cardiovascular events: A cohort study","volume":"9","author":"Alexander","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1523-1755.2005.00516.x","article-title":"Diabetes mellitus and the risk of nephrolithiasis","volume":"68","author":"Taylor","year":"2005","journal-title":"Kidney Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.293.4.455","article-title":"Obesity, weight gain, and the risk of kidney stones","volume":"293","author":"Taylor","year":"2005","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00240-021-01288-w","article-title":"Obesity-related indices and its association with kidney stone disease: A cross-sectional and longitudinal cohort study","volume":"50","author":"Lee","year":"2022","journal-title":"Urolithiasis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ekir.2023.01.034","article-title":"Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Urolithiasis","volume":"8","author":"Anan","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(06)68071-9","article-title":"Kidney stones: Pathophysiology and medical management","volume":"367","author":"Moe","year":"2006","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1046\/j.1523-1755.2003.00917.x","article-title":"Time trends in reported prevalence of kidney stones in the United States: 1976\u20131994","volume":"63","author":"Stamatelou","year":"2003","journal-title":"Kidney Int."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Akram, M., Jahrreiss, V., Skolarikos, A., Geraghty, R., Tzelves, L., Emilliani, E., Davis, N.F., and Somani, B.K. (2024). Urological Guidelines for Kidney Stones: Overview and Comprehensive Update. J. Clin. Med., 13.","DOI":"10.3390\/jcm13041114"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.juro.2016.05.090","article-title":"Surgical Management of Stones: American Urological Association\/Endourological Society Guideline, PART I","volume":"196","author":"Assimos","year":"2016","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/cphy.c210030","article-title":"Renal Tubular Handling of Glucose and Fructose in Health and Disease","volume":"12","author":"Vallon","year":"2021","journal-title":"Compr. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/dom.12962","article-title":"Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension","volume":"19","author":"Chilton","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu. Rev. Physiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11906-023-01281-1","article-title":"Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations","volume":"25","author":"Beal","year":"2023","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: A prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"120543","DOI":"10.1016\/j.lfs.2022.120543","article-title":"Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review","volume":"300","author":"Lingli","year":"2022","journal-title":"Life Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e2330885","DOI":"10.1001\/jamanetworkopen.2023.30885","article-title":"Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes","volume":"6","author":"Wie","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Rastogi, A., and Januzzi, J.L. (2023). Pleiotropic Effects of Sodium Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12082824"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"106524","DOI":"10.1016\/j.phrs.2022.106524","article-title":"Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation","volume":"186","author":"Anan","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00125-021-05424-4","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis","volume":"64","author":"Kristensen","year":"2021","journal-title":"Diabetologia"},{"key":"ref_44","first-page":"329","article-title":"Kidney stone formation and glycosuria in SGLT2 inhibitor-treated patients","volume":"83","author":"Torres","year":"2015","journal-title":"Clin. Nephrol."},{"key":"ref_45","first-page":"113","article-title":"Sodium-glucose cotransporter 2 inhibitors and kidney stone risk","volume":"16","author":"Wong","year":"2016","journal-title":"Curr. Diabetes Rep."},{"key":"ref_46","first-page":"820","article-title":"A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones","volume":"334","author":"Curhan","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_47","first-page":"1074","article-title":"SGLT2 inhibitors and the risk of kidney stones: Mechanistic insights and clinical implications","volume":"98","author":"Packer","year":"2020","journal-title":"Kidney Int."},{"key":"ref_48","first-page":"685","article-title":"Influence of glycosuria on urine pH and the risk of urinary stone formation","volume":"203","author":"Fujita","year":"2020","journal-title":"J. Urol."},{"key":"ref_49","first-page":"1","article-title":"The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the gut microbiome and oxalate metabolism","volume":"7","author":"Miller","year":"2017","journal-title":"Kidney Int. Suppl."},{"key":"ref_50","first-page":"2797","article-title":"Effect of SGLT2 inhibitors on uric acid metabolism","volume":"31","author":"Chino","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","first-page":"237","article-title":"The impact of SGLT-2 inhibitors on urinary citrate excretion and the potential implications for nephrolithiasis","volume":"5","author":"Amin","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_52","first-page":"345","article-title":"Calcium phosphate nephrolithiasis: An update on the pathophysiology and management","volume":"34","author":"Khan","year":"2016","journal-title":"World J. Urol."},{"key":"ref_53","first-page":"2279","article-title":"SGLT2 inhibitors and kidney stones: Preclinical to clinical evidence of risk and prevention strategies","volume":"9","author":"Bajaj","year":"2018","journal-title":"Diabetes Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.12439","article-title":"Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus","volume":"17","author":"Davies","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e3003","DOI":"10.1210\/clinem\/dgac154","article-title":"Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?","volume":"107","author":"Balasubramanian","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107808","DOI":"10.1016\/j.diabres.2019.107808","article-title":"Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials","volume":"155","author":"Cosentino","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2021111515","article-title":"Empagliflozin Changes Urine Supersaturation by Decreasing pH and Increasing Citrate","volume":"33","author":"Harmacek","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.juro.2016.04.086","article-title":"Topography, Composition and Structure of Incipient Randall Plaque at the Nanoscale Level","volume":"196","author":"Verrier","year":"2016","journal-title":"J. Urol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.juro.2018.06.029","article-title":"Short-Term Changes in Urinary Relative Supersaturation Predict Recurrence of Kidney Stones: A Tool to Guide Preventive Measures in Urolithiasis","volume":"200","author":"Ferraro","year":"2018","journal-title":"J. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e059073","DOI":"10.1136\/bmjopen-2021-059073","article-title":"Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): Protocol for a randomised, double-blind, placebo-controlled cross-over trial","volume":"12","author":"Schietzel","year":"2022","journal-title":"BMJ Open"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1523-1755.2005.00388.x","article-title":"Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: Osteopontin localization","volume":"68","author":"Evan","year":"2005","journal-title":"Kidney Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1359\/jbmr.080514","article-title":"Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney","volume":"23","author":"Okada","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00240-012-0514-y","article-title":"Biomolecular mechanism of urinary stone formation involving osteopontin","volume":"40","author":"Kohri","year":"2012","journal-title":"Urol. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12079-009-0068-0","article-title":"The role of osteopontin in inflammatory processes","volume":"3","author":"Lund","year":"2009","journal-title":"J. Cell Commun. Signal."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.juro.2012.05.078","article-title":"Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: Evidence from clinical and experimental investigations","volume":"189","author":"Khan","year":"2013","journal-title":"J. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Anan, G., Yoneyama, T., Noro, D., Tobisawa, Y., Hatakeyama, S., Sutoh Yoneyama, M., Yamamoto, H., Imai, A., Iwamura, H., and Kohada, Y. (2019). The Impact of Glycosylation of Osteopontin on Urinary Stone Formation. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010093"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.kint.2017.09.022","article-title":"The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1\u2013mediated tissue injury","volume":"93","author":"Anders","year":"2018","journal-title":"Kidney Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/ki.1995.222","article-title":"Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney","volume":"47","author":"Kleinman","year":"1995","journal-title":"Kidney Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.ASN.0000040593.93815.9D","article-title":"Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules","volume":"14","author":"Wesson","year":"2003","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/19\/6017\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:09:57Z","timestamp":1760112597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/19\/6017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":69,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["jcm13196017"],"URL":"https:\/\/doi.org\/10.3390\/jcm13196017","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]}}}